Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer

L. Bo; Y. K. Zhang; S. E. Reznik; Z. S. Chen

doi:10.1358/dof.2021.46.12.3313854

Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer

L. Bo, Y. K. Zhang, S. E. Reznik, Z. S. Chen

Pathology

Research output: Contribution to journal › Article › peer-review

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer deficient in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression. Due to these genetic mutations, its invasive nature and relatively poor response to drug therapy, TNBC remains a challenging clinical problem. Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in the regulation between immune stimulation and suppression in inflammation and cancer. Eganelisib is an immuno-oncology drug candidate that can selectively inhibit PI3Kγ and hinders the PI3K/AKT/mTOR signaling pathways. This article summarizes the characteristics and current treatment options for TNBC. We also present innovative multidrug combination systemic therapies for TNBC, which have been tested in preclinical and clinical studies using eganelisib.

Original language	English (US)
Pages (from-to)	963-975
Number of pages	13
Journal	Drugs of the Future
Volume	46
Issue number	12
DOIs	https://doi.org/10.1358/dof.2021.46.12.3313854
State	Published - Dec 2021

Keywords

Eganelisib
IPI-549
Immunotherapy
Multidrug resistance
PI3Kγ
Phosphoinositide-3-kinase γ
Triple-negative breast cancer

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1358/dof.2021.46.12.3313854

Cite this

@article{10ee0c787c8a4772aafb66085dfb1b8e,

title = "Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer",

abstract = "Triple-negative breast cancer (TNBC) is a subtype of breast cancer deficient in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression. Due to these genetic mutations, its invasive nature and relatively poor response to drug therapy, TNBC remains a challenging clinical problem. Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in the regulation between immune stimulation and suppression in inflammation and cancer. Eganelisib is an immuno-oncology drug candidate that can selectively inhibit PI3Kγ and hinders the PI3K/AKT/mTOR signaling pathways. This article summarizes the characteristics and current treatment options for TNBC. We also present innovative multidrug combination systemic therapies for TNBC, which have been tested in preclinical and clinical studies using eganelisib.",

keywords = "Eganelisib, IPI-549, Immunotherapy, Multidrug resistance, PI3Kγ, Phosphoinositide-3-kinase γ, Triple-negative breast cancer",

author = "L. Bo and Zhang, {Y. K.} and Reznik, {S. E.} and Chen, {Z. S.}",

note = "Publisher Copyright: {\textcopyright} 2021 Clarivate.",

year = "2021",

month = dec,

doi = "10.1358/dof.2021.46.12.3313854",

language = "English (US)",

volume = "46",

pages = "963--975",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "12",

}

TY - JOUR

T1 - Eganelisib

T2 - Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer

AU - Bo, L.

AU - Zhang, Y. K.

AU - Reznik, S. E.

AU - Chen, Z. S.

PY - 2021/12

Y1 - 2021/12

N2 - Triple-negative breast cancer (TNBC) is a subtype of breast cancer deficient in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression. Due to these genetic mutations, its invasive nature and relatively poor response to drug therapy, TNBC remains a challenging clinical problem. Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in the regulation between immune stimulation and suppression in inflammation and cancer. Eganelisib is an immuno-oncology drug candidate that can selectively inhibit PI3Kγ and hinders the PI3K/AKT/mTOR signaling pathways. This article summarizes the characteristics and current treatment options for TNBC. We also present innovative multidrug combination systemic therapies for TNBC, which have been tested in preclinical and clinical studies using eganelisib.

AB - Triple-negative breast cancer (TNBC) is a subtype of breast cancer deficient in estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) expression. Due to these genetic mutations, its invasive nature and relatively poor response to drug therapy, TNBC remains a challenging clinical problem. Phosphoinositide-3-kinase γ (PI3Kγ) plays a critical role in the regulation between immune stimulation and suppression in inflammation and cancer. Eganelisib is an immuno-oncology drug candidate that can selectively inhibit PI3Kγ and hinders the PI3K/AKT/mTOR signaling pathways. This article summarizes the characteristics and current treatment options for TNBC. We also present innovative multidrug combination systemic therapies for TNBC, which have been tested in preclinical and clinical studies using eganelisib.

KW - Eganelisib

KW - IPI-549

KW - Immunotherapy

KW - Multidrug resistance

KW - PI3Kγ

KW - Phosphoinositide-3-kinase γ

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85122256564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122256564&partnerID=8YFLogxK

U2 - 10.1358/dof.2021.46.12.3313854

DO - 10.1358/dof.2021.46.12.3313854

M3 - Article

AN - SCOPUS:85122256564

SN - 0377-8282

VL - 46

SP - 963

EP - 975

JO - Drugs of the Future

JF - Drugs of the Future

IS - 12

ER -

Eganelisib: Phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitor Treatment of triple-negative breast cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this